CombiCTx: screening diffusion gradients of anti-cancer drug combinations

Area of Science:

• Oncology
• Drug Discovery
• Biotechnology

Background:

• Chemotherapy resistance limits treatment efficacy.
• Tumor microenvironment dynamics impact drug response.
• Novel drug combinations are needed to overcome resistance.

Purpose of the Study:

• Develop a novel assay for combinatorial chemotherapeutic (CTx) screening.
• Evaluate drug interactions and diffusion in a 3D tumor model.
• Inform new clinical treatment strategies by assessing drug combinations.

Main Methods:

• Developed CombiCTx assay with drug-loaded gel reservoirs.
• Used time-lapse microscopy to image drug diffusion (doxorubicin).
• Quantified cancer cell survival responses along dynamic drug gradients.

Main Results:

• CombiCTx successfully evaluated cytotoxic effects of drug combinations.
• Navitoclax showed localized effects due to limited diffusion.
• Gemcitabine diffused readily, revealing mild synergy with navitoclax.

Conclusions:

• CombiCTx accounts for drug diffusion differences in 3D tumor models.
• The assay can inform development of effective anti-cancer drug combinations.
• This approach may improve clinical treatment strategies for cancer.